The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.
Thierry Conroy
No relevant relationships to disclose
Marie-Pierre Galais
No relevant relationships to disclose
Jean Luc Raoul
No relevant relationships to disclose
Olivier Bouche
No relevant relationships to disclose
Sophie Gourgou-Bourgade
No relevant relationships to disclose
Jean-Yves Douillard
No relevant relationships to disclose
Pierre-Luc Etienne
No relevant relationships to disclose
Valérie Boige
No relevant relationships to disclose
Isabelle Martel-Lafay
No relevant relationships to disclose
Pierre Michel
No relevant relationships to disclose
Carmen Llacer-Moscardo
No relevant relationships to disclose
Jocelyne Berille
Research Funding - Sanofi
Laurent Bedenne
No relevant relationships to disclose
Antoine Adenis
No relevant relationships to disclose